Bain Capital Life Sciences Investors’s ARYA Sciences Acquisition Corp IV Class A Odinary Shares ARYD Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ARYD Stock Details ARYD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-700,000	Closed	-$6.87M	–	34
2022 Q2	$6.87M	Hold	700,000	–	–	0.81%	24
2022 Q1	$6.86M	Hold	700,000	–	–	0.67%	26
2021 Q4	$6.94M	Hold	700,000	–	–	0.55%	25
2021 Q3	$7.04M	Hold	700,000	–	–	0.44%	26
2021 Q2	$7.5M	Hold	700,000	–	–	0.49%	24
2021 Q1	$7.33M	Buy	+700,000	New	+$7.56M	0.42%	25

Other funds holding ARYD

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.61% 1-Year Est. Return

Bain Capital Life Sciences Investors's ARYD Position: Q3 2022 in Review

Bain Capital Life Sciences Investors sold out of ARYA Sciences Acquisition Corp IV Class A Odinary Shares (ARYD) in Q3 2022, closing a stake of 700,000 shares — an estimated $6.87M sold.

Bain Capital Life Sciences Investors first reported a position in ARYD in Q1 2021 and held it in 6 quarters. The position peaked at $7.5M in Q2 2021. 55 funds tracked by Wall St. Rank hold ARYD as of Q3 2022.

Bain Capital Life Sciences Investors reported no remaining ARYA Sciences Acquisition Corp IV Class A Odinary Shares position as of Q3 2022 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 700,000 ARYA Sciences Acquisition Corp IV Class A Odinary Shares shares in Q3 2022, an estimated $6.87M.
Bain Capital Life Sciences Investors first reported a position in ARYA Sciences Acquisition Corp IV Class A Odinary Shares in Q1 2021 and held it in 6 quarters.
Bain Capital Life Sciences Investors's ARYA Sciences Acquisition Corp IV Class A Odinary Shares position peaked at $7.5M in Q2 2021.
55 funds tracked by Wall St. Rank held ARYA Sciences Acquisition Corp IV Class A Odinary Shares as of Q3 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2022, filed 14 Nov 2022.